Growth Rate of Ovarian Serous Cystadenomas and Cystadenofibromas.
cystadenofibroma
cystadenoma
doubling time
growth rate
ovary
Journal
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
ISSN: 1550-9613
Titre abrégé: J Ultrasound Med
Pays: England
ID NLM: 8211547
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
30
11
2020
accepted:
02
12
2020
pubmed:
16
12
2020
medline:
22
9
2021
entrez:
15
12
2020
Statut:
ppublish
Résumé
We analyzed growth rates of benign ovarian serous cystadenomas and cystadenofibromas to understand what percentage would show a volume doubling time (DT) of less than 3 years, between 3 and 5 years, or greater than 5 years. We retrospectively reviewed pathology records (January 1, 2014, to June 30, 2019) to find all surgically excised ovarian serous cystadenomas and cystadenofibromas. Imaging records were then reviewed to identify those that had been confidently identified with ultrasound imaging, magnetic resonance imaging, or computed tomography at least twice before surgical removal, with at least a 60-day interval between studies. Three orthogonal measurements were recorded on the first and last imaging studies on which the mass was detected, with volume calculations by the prolate formula (product of 3 measurements multiplied by 0.52). The volume DT was calculated and grouped into 1 of 5 categories: (1) DT of less than 1 year; (2) DT of 1 to 3 years; (3) DT of 3 to 5 years; (4) DT of 5 to 10 years; and (5) no growth (any mass with a DT >10 years or showing a decrease in volume). A total of 102 of 536 cystadenomas and 44 of 227 cystadenofibromas met inclusion criteria. Of the 146 tumors, 40 (27.4%) had a DT of less than 1 year; 38 (26.0%) had a DT of 1 to 3 years; 22 (15.1%) had a DT of 3 to 5 years; 10 (6.8%) had a DT of 5 to 10 years; and 36 (24.7%) showed no growth. A total of 53.4% of ovarian serous cystadenomas/cystadenofibromas have a DT of less than 3 years; 15.1% have a DT between 3 and 5 years; and 31.5% have a DT of greater than 5 years or show no growth.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2123-2130Informations de copyright
© 2020 American Institute of Ultrasound in Medicine.
Références
Patel MD, Ascher SM, Horrow MM, et al. Management of incidental adnexal findings on CT and MRI: a white paper of the ACR Incidental Findings Committee. J Am Coll Radiol 2020; 17:248-254.
Levine D, Patel MD, Suh-Burgmann EJ, et al. Simple adnexal cysts: SRU consensus conference update on follow-up and reporting. Radiology 2019; 293:359-371.
American College of Obstetricians and Gynecologists. Practice Bulletin No. 174: evaluation and management of adnexal masses. Obstet Gynecol 2016; 128:e210-e226.
Gonzalez DO, Minneci PC, Deans KJ. Management of benign ovarian lesions in girls: a trend toward fewer oophorectomies. Curr Opin Obstet Gynecol 2017; 29:289-294.
Guraslan H, Dogan K. Management of unilocular or multilocular cysts more than 5 centimeters in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2016; 203:40-43.
Patel MD. Practical approach to the adnexal mass. Radiol Clin North Am 2006; 44:879-899.
Sarkar M, Wolf MG. Simple ovarian cysts in postmenopausal women: scope of conservative management. Eur J Obstet Gynecol Reprod Biol 2012; 162:75-78.
Modesitt SC, Pavlik EJ, Ueland FR, DePriest PD, Kryscio RJ, van Angell NJR. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 2003; 102:594-599.
Nardo LG, Kroon ND, Reginald PW. Persistent unilocular ovarian cysts in a general population of postmenopausal women: is there a place for expectant management? Obstet Gynecol 2003; 102:589-593.
Valentin L, Skoog L, Epstein E. Frequency and type of adnexal lesions in autopsy material from postmenopausal women: ultrasound study with histological correlation. Ultrasound Obstet Gynecol 2003; 22:284-289.
Seidman JD, Mehrotra A. Benign ovarian serous tumors: a re-evaluation and proposed reclassification of serous “cystadenomas” and “cystadenofibromas.”. Gynecol Oncol 2005; 96:395-401.
Erickson BK, Conner MG, Landen CN Jr. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol 2013; 209:409-414.
Parazzini F, Frattaruolo MP, Chiaffarino F, Dridi D, Roncella E, Vercellini P. The limited oncogenic potential of unilocular adnexal cysts: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2018; 225:101-109.
Brauer VF, Eder P, Miehle K, Wiesner TD, Hasenclever H, Paschke R. Interobserver variation for ultrasound determination of thyroid nodule volumes. Thyroid 2005; 15:1169-1175.
Schwartz M. A biomathematical approach to clinical tumor growth. Cancer 1961; 14:1272-1294.
Song YS, Park CM, Park SJ, Lee SM, Jeon YK, Goo JM. Volume and mass doubling times of persistent pulmonary subsolid nodules detected in patients without known malignancy. Radiology 2014; 273:276-284.
Li J, Xia T, Yang X, et al. Malignant solitary pulmonary nodules: assessment of mass growth rate and doubling time at follow-up CT. J Thorac Dis 2018; 10:S797-S806.
Cheng EJ, Kurman RJ, Wang M, et al. Molecular genetic analysis of ovarian serous cystadenomas. Lab Invest 2004; 84:778-784.